Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
ONT reported £ 150 million loss and shares are up , LGEN profit in 2023 of GBP1.67 billion and shares are down, WTF
Oxford Nanopore is based in Oxford, England, and specialises in DNA and RNA sequencing technologies.
Oxford Nanopore's pretax loss was GBP149.8 million in 2023, widened 80% from GBP83.4 million a year prior.
Revenue dropped 15% to GBP169.7 million from GBP198.6 million in 2022.
Bit disappointing to see their break even EBITDA target pushed to '27 but they have the cash runway. Happy to see Covid and Emirati revenue distortions wound down. Their confidence in achieving >30% CAGR is positive. I wonder if there is any buyout interest with the share price so low.
Clearly the market isnt expecting much anymore from them, be £1 soon
i hope it’s not we’ve lost a **** ton of money but we have a plan on the 6th
Final Results 06-Mar-2024
Not sure mr market has a lot of love for ONT anymore - abysmal SP performance
Well, JPM unwound their short pretty quickly leaving a really nice looking setup on the chart. The deferring of some of the China revenue could result in stronger than expected guidance for FY '24
Share price is up in two days and now could we see 165p tomorrow .
Looks like JPM are short since Jan 11. No wonder the share price has been getting crushed
Really poor sales growth. Sangera not running this business very well.
Makes no mention of how much grant the Australians have been awarded? Interesting and encouraging but financially small beer imo.
Followed both these UK co's from private. LSE v Nasdaq. Similar post covid down trends. Seems however $LMDX have a buyer and an exit in process as CEO makes way.
Good to have Apple Inc showcasing our product with their new chip launch.
I too hold both.
The thing that's knocked my confidence in PACB was their Apto bioscience purchase and the $100m dilution to us in order to purchase.
$100m in this current high interest rate environment for a company with no tangible product is insane. Paid way too much. $85m upfront is too much. Should have been $50m or less upfront and then strict milestones with conservative milestones, in order to trigger the final $50m (still too much).
As well, don't forget that there was approx $100m dilution from the Omniome purchase. at the beginning of October. We don't even know how stellar the Onso product sales will be . They have to be pressed to provide a backlog number and a GM.
Ha! What difference a day makes!
Buy while you can, will soon be 250+. I have large holding in ONT and in Pacific Biosciences. Both technologies and companies are superb. I'm in for the long game but expect short term boost here from today : )
I would hope that the RNS ref Mayo Clinic will lift the sp this afternoon?
RNS X 3 this morning might help!
Looking pretty grim here right now. Any thoughts on potential catalysts in the near future?
Once you writedown COVID related revenue to zero, we can look at the business on normal terms.
COVID testing was always going to wane. Its whether they can use the one-time COVID money to advance their products and research elsewhere.
What a turd, £70M loss - It was so over hyped when it floated now reality has set in and it’s ugly.
Nice Revenue growith confirmation
Surprisingly , sp, has retreated from its high, back below the recent pivot, I mentioned. Closing price is important, so now, there is no bullish pivot break upward. I was expecting may be a retreat of day 5 from the high, but complete retreat unexpected. Sp, action before today was bullish, so I am designating this a hold until the pivot, I mentioned, is crossed above on a closing price basis .
Sp, broke above pivot of 12/7/23, which is bullish. Relative strength indicator crossed above 50, indicated trend up resumed . Sp, is also above the day on 15/6/23, when 40 million shares were traded, not surprisingly because sp, was falling before that trade. Price target 265, based on gradually falling major down trendline.
If that is behind a paywall for you, just drop the headline into a search engine - it’s all over the web.